Evidence map›Paper›PMID 34471015›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.

Tomoko Mizuno, Naoko Inoshita, Noriaki Fukuhara, Keita Tatsushima, Akira Takeshita, Shozo Yamada, Hiroshi Nishioka, Yasuhiro Takeuchi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tomoko MizunoDepartment of Endocrinolgy and Metabolism, Toranomon Hospital, Japan.
Naoko InoshitaDepartment of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Hospital, Japan.
Noriaki FukuharaDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan.
Keita TatsushimaDepartment of Endocrinolgy and Metabolism, Toranomon Hospital, Japan.
Akira TakeshitaDepartment of Endocrinolgy and Metabolism, Toranomon Hospital, Japan.
Shozo YamadaDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan.
Hiroshi NishiokaDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan.
Yasuhiro TakeuchiDepartment of Endocrinolgy and Metabolism, Toranomon Hospital, Japan.
Toranomon Hospital · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas.

Indexed as

Pituitary ACTH HypersecretionReceptors, SomatostatinAdultHumansMaleSomatostatinpasireotideReceptors, SomatostatinSomatostatinsomatostatin receptor 5corticotroph adenomaCushing's diseasepasireotidesomatostatin receptor 5USP8 mutation

Identifiers

PMID34471015
PMCPMC8943369
OpenAlexW3196952705

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.